Neuronetics vs Tactile Systems Technology
STIM and TCMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STIM and TCMD compare
Tactile Systems Technology is the larger company, worth 5.7 times as much as Neuronetics ($607M against $106M).
Neuronetics grew revenue faster over the last twelve months (23.0% versus 14.4% for Tactile Systems Technology).
Tactile Systems Technology keeps more of each dollar of sales as profit, with a net margin of 6.7% compared with −14.4% at Neuronetics.
Tactile Systems Technology scores higher on the StockData Score (16 against 5 for Neuronetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STIM | TCMD |
|---|---|---|
| Size and price | ||
| Market cap | $106M | $607M |
| Share price | $1.39 | $26.81 |
| Change, 1 year | −35.6% | 9.0% |
| Change, 5 years | −65.3% | 13.8% |
| Beta (5Y) | 1.59 | 1.33 |
| Employees | 658 | 1,086 |
| StockData Score | ||
| Total score | 5 | 16 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 | 3 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 26.0× |
| P/S | 0.7× (better) | 1.7× |
| P/B | 5.7× | 2.7× (better) |
| EV/EBITDA | – | 13.1× |
| P/FCF | – | 20.9× |
| FCF yield | −9.1% | 4.8% (better) |
| Fair value | – | $25.21 |
| Margin of safety | – | −6.3% |
| Growth | ||
| Revenue growth (TTM) | 23.0% (better) | 14.4% |
| Revenue growth, 5Y average | 24.8% (better) | 12.0% |
| Net income growth (TTM) | – | 31.1% |
| EPS growth (TTM) | – | 33.8% |
| Profitability | ||
| Gross margin | 50.7% | 77.0% (better) |
| Operating margin | −9.4% | 9.4% (better) |
| Net margin | −14.4% | 6.7% (better) |
| FCF margin | −6.0% | 8.1% (better) |
| Return on equity | −100% | 11.0% (better) |
| Return on invested capital | −19.2% | 15.3% (better) |
| Financial health | ||
| Debt / equity | 3.30 (better) | 0.00 |
| Interest coverage | −1.7× | 432× (better) |
| Current ratio | 2.01 | 3.51 (better) |
| Altman Z-score | −3.38 | 8.11 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 48.8% | 96.7% |
| Held by insiders | 51.3% | 4.4% |
| Insider net buying, 12 months | $4.6M (better) | −$2.3M |
| Short interest, % of float | 18.0% | 12.9% |
Go deeper
- STIM stock overview
- STIM income statement
- STIM valuation and score
- TCMD stock overview
- TCMD income statement
- TCMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.